Cytokinetics, Incorporated (CYTK) Position Lowered by SG Americas Securities LLC
SG Americas Securities LLC lowered its stake in Cytokinetics, Incorporated (NASDAQ:CYTK) by 46.9% during the first quarter, Holdings Channel reports. The fund owned 8,254 shares of the biopharmaceutical company’s stock after selling 7,297 shares during the period. SG Americas Securities LLC’s holdings in Cytokinetics, were worth $106,000 as of its most recent SEC filing.
A number of other institutional investors also recently added to or reduced their stakes in the company. Norges Bank bought a new position in Cytokinetics, during the fourth quarter valued at $976,000. Teachers Advisors LLC increased its position in Cytokinetics, by 4.0% in the fourth quarter. Teachers Advisors LLC now owns 53,278 shares of the biopharmaceutical company’s stock valued at $647,000 after buying an additional 2,025 shares during the last quarter. Acadian Asset Management LLC bought a new position in Cytokinetics, during the first quarter valued at $4,302,000. Shell Asset Management Co. bought a new position in Cytokinetics, during the first quarter valued at $551,000. Finally, Russell Investments Group Ltd. bought a new position in Cytokinetics, during the first quarter valued at $2,137,000. 58.58% of the stock is owned by institutional investors.
Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) opened at 13.90 on Tuesday. The stock’s 50 day moving average price is $13.99 and its 200 day moving average price is $12.72. Cytokinetics, Incorporated has a 12-month low of $8.51 and a 12-month high of $17.20. The firm has a market cap of $626.65 million, a PE ratio of 187.84 and a beta of 1.97.
TRADEMARK VIOLATION NOTICE: This story was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/07/18/cytokinetics-incorporated-cytk-position-lowered-by-sg-americas-securities-llc.html.
Several equities analysts have weighed in on CYTK shares. Rodman & Renshaw reissued a “buy” rating and set a $25.00 price target on shares of Cytokinetics, in a research report on Thursday, March 23rd. HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of Cytokinetics, in a research report on Tuesday, April 25th. Cowen and Company reissued an “outperform” rating and set a $19.00 price target (up previously from $17.00) on shares of Cytokinetics, in a research report on Saturday, April 29th. Zacks Investment Research downgraded Cytokinetics, from a “hold” rating to a “strong sell” rating in a research report on Thursday, May 4th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Cytokinetics, in a research report on Friday, May 19th. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $20.40.
In other Cytokinetics, news, CEO Robert I. Blum sold 5,000 shares of the business’s stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $13.62, for a total transaction of $68,100.00. Following the sale, the chief executive officer now directly owns 94,785 shares of the company’s stock, valued at approximately $1,290,971.70. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 7.20% of the stock is owned by insiders.
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.
Want to see what other hedge funds are holding CYTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytokinetics, Incorporated (NASDAQ:CYTK).
Receive News & Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.